

Atherosclerosis in SLE: a potential role for serum parathormone levels

Mayra Giannelou,^{1,2} Charalampos Skarlis ,³ Aikaterini Stamouli,⁴ Eleni Antypa,⁵ Haralampos M Moutsopoulos,⁶ Clio P Mavragani^{3,7}

To cite: Giannelou M, Skarlis C, Stamouli A, *et al.* Atherosclerosis in SLE: a potential role for serum parathormone levels. *Lupus Science & Medicine* 2020;7:e000393. doi:10.1136/lupus-2020-000393

Data from this manuscript have been previously presented in an abstract form https://ard.bmj.com/content/78/Suppl_2/1720.2

Received 21 February 2020
Revised 28 June 2020
Accepted 7 July 2020

ABSTRACT

Objective A link between bone metabolism and cardiovascular (CV) disease has been suggested mainly in the general population. In the current study we explored whether altered bone metabolism influence CV risk in patients with SLE.

Methods In 138 consecutive patients with SLE, atherosclerosis was assessed by the presence of plaque and/or arterial wall thickening in carotid/femoral arteries by ultrasound. Bone mineral density (BMD) levels and hip/spinal cord fractures together with classical CV disease and osteoporosis risk factors including serum 25(OH) vitamin D₃ and parathormone (PTH) levels were recorded in all patients. Serum osteoprotegerin (OPG) and receptor activator of nuclear factor kappa-B ligand were quantitated by commercial ELISA. Statistical analysis included both univariate and multivariate models.

Results Abnormal PTH serum concentrations (>65 pg/mL)—but not 25(OH) vitamin D₃ serum levels—were identified as a risk factor for both plaque formation and arterial wall thickening in patients with SLE (ORs (95% CIs): 8.2 (1.8 to 37.4) and 3.9 (1.3 to 11.8), respectively). This association remained significant following adjustment for vitamin D₃ levels and classical CV risk factors. Moreover, an independent association between osteoporosis with plaque formation and arterial wall thickening was detected following adjustment for total steroid dose, premature menopause and disease duration (ORs (95% CIs): 5.3 (1.1 to 26.2) and 3.5 (1.1 to 11.4), respectively). An inverse correlation between femoral neck BMD values and intima-medial thickness scores was also observed (r: -0.42, p=0.008).

Conclusions These findings further strengthen the concept of shared pathophysiological mechanisms between atherogenesis and altered bone metabolism in autoimmune populations, revealing heightened PTH levels as a potential marker for atherosclerosis among patients with SLE.

INTRODUCTION

In the general population, osteoporosis and cardiovascular disease (CVD) have been perceived not only as coexisting conditions of the elderly but also as inter-related disorders affecting both sexes^{1,2}; therefore, the idea of a common, yet unknown link in the pathogenesis of both entities seems appealing.³ Alterations in the osteoprotegerin (OPG)/

receptor activator of nuclear factor kappa-B ligand (RANKL) axis have been previously postulated as common denominators. Indeed, the contribution of bone metabolism markers such as OPG or osteopontin has been previously shown to serve as surrogate markers for CVD.⁴ Moreover, OPG-deficient mice displayed increased atherosclerosis, vascular calcification and osteoporosis together with heightened circulating RANKL levels.⁵

A candidate molecule which attracted particular attention in recent years is 25(OH) vitamin D₃ (25-OHD), due to pleiotropic functions extending beyond bone mineralisation and calcium homeostasis. Therefore, the presence of 25-OHD receptors in cardiovascular (CV) tissue cells^{6,7} and the associations of low 25-OHD concentrations with myocardial infarction, extent of coronary artery disease and worse CV-related clinical outcome^{8,9} support this concept. A number of studies, though not all, have also reported associations of low 25-OHD levels with subclinical atherosclerosis.¹⁰⁻¹³ In addition, parathormone (PTH)—traditionally considered an endogenous biological marker of 25-OHD deficiency—has also been linked to coronary heart disease¹⁴ and CV mortality.¹⁵

A growing body of evidence over the last years revealed an excessive burden of both CVD and impaired bone health in patients with systemic autoimmune disorders.¹⁶⁻¹⁸ For instance, in SLE, heightened rates of both subclinical atherosclerosis,¹⁶ osteoporosis as well as peripheral and vertebral fractures have been repeatedly reported.^{19,20} Moreover, low 25-OHD levels (<20 ng/mL) were found to be prevalent in patients with SLE.²¹ This is a rather unsurprising finding given that patients with SLE are advised to avoid sun exposure, often suffer from renal dysfunction and are subjected to medication affecting 25-OHD metabolism, such as antimalarials and corticosteroids; in addition, disease activity has been found to decrease 25-OHD concentrations.²¹



© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

For numbered affiliations see end of article.

Correspondence to

Dr Clio P Mavragani;
kmauragan@med.uoa.gr

In the present study, we sought to investigate whether 25-OHD deficiency and/or increased PTH levels, as well as bone density alterations, influence atherosclerosis in patients with SLE.

METHODS

Study subjects

In the present study, 138 consecutive patients with SLE (mean age \pm SD: 44.7 \pm 13.6, female prevalence: 94%) according to the American College of Rheumatology 2012 criteria for the classification of SLE²² were included. All patients were followed by HMM, CPM and MG. Criteria exclusion included age <18 years old, pregnancy and renal dysfunction (serum creatinine levels >3 mg/dL, creatinine clearance <30 mL/min). All participants provided informed consent prior to study entry. Patients with prior CV events were not excluded.

Assessment of atherosclerosis and impaired bone health

All study participants were evaluated by ultrasound for carotid and/or femoral plaque detection. Additionally, measurement of intima–medial thickness (IMT) scores at the same sites was performed in 125 SLE and mean scores were calculated as previously described. IMT score higher than 0.90 mm was defined as arterial wall thickening.²³ In detail, both the carotid (common carotid, bifurcation and internal carotid) and the femoral (common femoral and superficial femoral) arteries were evaluated in each individual by ultrasound (iU22; Philips, Royal Philips Electronics of the Netherlands). The mean carotid artery IMT was defined as the average of 36 IMT readings (common, bifurcation, and internal carotid arteries, right and left side, far and near wall, with three sampling points per segment) and the mean femoral artery IMT was the average of 24 IMT readings (common and superficial femoral arteries, right and left sides, far and near wall, with three sampling points per segment), as previously described.²³ Plaque formation was defined as a focal protrusion of more than 50% of the surrounding wall.²⁴ The radiologist (EA) in charge of the ultrasound scanning was unaware of the clinical diagnosis of the subjects under evaluation.

Bone mineral density (BMD) measurements were performed in all study participants using dual X-ray absorptiometry QDR4500 (Hologic). BMD measurements were performed either on the spine or hip, according to age.²⁵ Thus, in patients <65 years old, BMD was measured on the spine, while in those >65 years old, BMD was measured on the hip. For postmenopausal women and men \geq 50 years old, the presence of osteoporosis or osteopaenia was defined according to the WHO classification system, as a T-score less than -2.5 SDs and -1 SDs, respectively, at either site of measurement. For premenopausal patients or men aged <50 years, the Z-score for low BMD was implemented, with z-score less than -2 SD considered low BMD for chronological age.²⁶ Lateral radiographs of the thoracic and lumbar spine were implemented to

identify asymptomatic vertebral fractures by semiquantitative evaluation.²⁷ Vitamin D deficiency was defined as serum 25-OHD levels lower than 20 ng/mL, while cut-off value for high PTH levels was set as 65 pg/mL, as previously suggested.²⁸

Disease and traditional risk factors for atherosclerosis and impaired bone health

Demographic data (age, sex and body mass index (BMI)), clinical and laboratory features, disease activity/damage scores (SLEDAI: Systemic Lupus Erythematosus Disease Activity Index, SLICC: Systemic Lupus International Collaborating Clinics), current and prior medications, traditional risk factors for atherosclerosis and osteoporosis and bone metabolism parameters were thoroughly recorded as previously described.^{29,30} Additionally, all patients underwent evaluation for traditional CVD risk factors such as serum cholesterol, triglyceride and homocysteine levels as well as bone metabolism markers including PTH and 25-OHD serum levels. Blood was drawn in the morning in fasting conditions.

OPG and RANKL quantitation

To explore whether the RANK/RANKL/OPG signalling pathway is implicated in the pathogenesis of SLE-related atherosclerosis, OPG/RANKL levels were determined in available sera from 28 patients with SLE by commercial ELISA, as per manufacturer instructions.

Statistical analysis

Two-sided Fisher's exact and Mann-Whitney or Kruskal-Wallis tests were used to compare qualitative and quantitative characteristics, respectively, and ORs with 95% CIs were calculated. To test whether osteoporosis (independent variable) was associated with plaque formation (dependent variable) in SLE, a multivariate backwards stepwise model including SLE-related shared risk factors for both entities such as disease duration, total steroid dose, premature menopause was constructed. Similarly, to assess whether PTH levels (independent variable) are associated with plaque formation or arterial wall thickening (dependent variables) independently of 25-OHD serum levels and other potential confounders for CV risk, a second multivariate model was implemented. Pearson's correlation coefficient analyses were used for the detection of a relationship between IMT and BMD values in patients with SLE. A p-value of less than 0.05 for univariate analyses and 0.1 for multivariate analyses, respectively, were considered statistically significant. Data were analysed by the SPSS V.25.0 statistical package.

RESULTS

Contributors of atherosclerosis in SLE

Traditional and disease-related risk factors

As shown in [table 1](#), and in line with previous reports, traditional CV risk factors and disease-related features have been both found to account for plaque formation and/or arterial wall thickening among patients with

Table 1 Contribution of traditional and disease-related risk factors in carotid/femoral plaque formation and arterial wall thickening (IMT >0.90 mm) among patients with SLE

	Plaque (n=77)	No plaque (n=61)	P value	IMT >0.9 mm (n=49)	IMT ≤0.9 mm (n=76)	P value
Traditional risk factors						
Age (mean±SD), years	52.1±11.2	35.0±10.1	<0.0001	55.1±10.7	38.1±11.1	<0.0001
BMI (mean±SD), kg/m ²	26.6±5.6	23.7±4.6	0.002	27.7±5.7	23.8±4.6	<0.0001
Smoking (mean±SD), pack/years	12.3±17.2	6.3±10.2	ns	13.6±19.4	7.3±10.6	ns
FH of CVD (%)	22.7	18.6	ns	20.0	21.4	ns
Diabetes (%)	10.4	3.3	ns	13.5	3.5	0.04
Hypertension (%)	46.8	11.5	<0.0001	55.8	16.3	<0.0001
Cholesterol (mean±SD), mg/dL	189±34	181±41	ns	192±38	182±37	ns
HDL (mean±SD), mg/dL	49±15	53±23	ns	48±13	52±22	ns
LDL (mean±SD), mg/dL	113±36	104±33	ns	117±37	107±33	ns
Triglycerides (mean±SD), mg/dL	125±48	104±53	0.003	130±53	104±49	0.008
Premature menopause (%)	11.0	5.0	ns	6.5	10	ns
Women at menopause (%)	58.1	15.2	<0.00001	71.1	20.7	<0.00001
Disease-related risk factors						
Disease duration (mean±SD), years	12.4±9.7	5.8±5.7	0.0001	11.8±10.0	8.0±7.6	0.02
SLEDAI (mean±SD)	8.6±6.8	9.2±7.8	ns	8.5±6.9	9.1±7.4	ns
Current steroid dose (mean±SD), mg	9.0±12.5	11.0±14.0	ns	6.9±11.6	12.3±14.3	0.008
Total steroid dose (mean±SD), g	33.9±32.9	16.4±22.6	0.003	29.7±31.2	24.0±29.2	ns
% of patients on steroids	77.9	80.3	ns	67.3	84.8	0.03

BMI, body mass index; CVD, cardiovascular disease; FH, family history; HDL, high-density lipoprotein; IMD, intima-media thickness; LDL, low-density lipoprotein; ns, non-significant; SLEDAI, Systemic Lupus Erythematosus Disease Activity Index.

SLE.³¹ Age, BMI, hypertension, triglycerides, menopausal status and disease duration were found to be associated with both plaque formation and high IMT scores, while total steroid dose with plaque. A protective role for higher current steroid dose for arterial wall thickening was also observed. In the entire cohort, two patients had a history of stroke and one patient a history of stroke and coronary artery disease (data not shown).

Bone metabolism regulators/markers

We next wished to explore whether bone metabolism-related features can contribute to atherosclerosis among patients with SLE.

As shown in [table 2](#), PTH levels were found to be significantly increased in patients with SLE with plaque formation and/or arterial wall thickening compared with those without (51.1±27.7 vs 37.4±18.4 pg/mL, p=0.003 and 54.0±32.7 vs 40.0±18.3 pg/mL, p=0.02, respectively). Moreover, as shown in both [figure 1A,C](#) and [table 2](#), the presence of hyperparathyroidism

(defined as PTH serum levels >65 pg/mL) was also found to be significantly associated with plaque formation and arterial wall thickening (25% vs 3.9%, p=0.002 and 27% vs 8.7%, p=0.012, respectively) and was therefore identified as a risk factor for both plaque formation and arterial wall thickening (ORs (95% CIs): 8.2 (1.8 to 37.4) and 3.9 (1.3 to 11.8), respectively). No association was observed between plaque or arterial wall thickening with 25-OHD levels or 25-OHD deficiency ([figure 1B,D](#); [table 2](#)) serum or urine calcium and phosphate levels and collagen cross-links CTX (C-terminal telopeptide of type I collagen) and NTX (N-terminal telopeptide of type I collagen) ([table 2](#)). No patient was on PTH or denosumab. Following adjustment for 25-OHD levels, diabetes, hypertension, high cholesterol (>200 mg/dL) and triglyceride (>150 mg/dL) levels, increased BMI (more than 25 kg/m²), advanced age (>70 years old) and menopausal status, the association between PTH levels with plaque

Table 2 Contribution of bone metabolism features in carotid/femoral plaque formation and arterial wall thickening (IMT>0.90mm) among patients with SLE

	Plaque	No plaque	P value	IMT >0.9mm	IMT ≤0.9mm	P value
Bone metabolism markers						
PTH (mean±SD), pg/mL	51.1±27.7	37.4±18.4	0.003	54.0±32.7	40.0±18.3	0.02
Hyperparathyroidism (>65 pg/mL) (%)	25.0	3.9	0.002	27	8.7	0.012
25-OHD (mean±SD), ng/mL	20.2±9.4	20.2±8.4	ns	20.0±9.7	19.9±8.7	ns
Vitamin D deficiency (<20 ng/mL) (%)	50.8	50.9	ns	58.3	51.4	ns
Ca (mean±SD), mmol/L	9.4±0.5	9.4±0.4	ns	9.4±0.5	9.4±0.4	ns
P (mean±SD), mmol/L	3.4±0.6	3.3±0.6	ns	3.5±0.6	3.3±0.6	ns
Ca urine (mean±SD), g/24 hours	0.13±0.13	0.16±0.20	ns	0.09±0.06	0.16±0.19	ns
P urine (mean±SD), g/24 hours	0.65±0.37	0.58±0.32	ns	0.60±0.25	0.64±0.40	ns
CTX (mean±SD), ng/mL	0.35±0.28	0.39±0.28	ns	0.38±0.34	0.35±0.25	ns
NTX (mean±SD) ng/mL	36.8±29.3	35.6±27.2	ns	38.4±33.7	35.4±26.5	ns
Disorders of bone metabolism						
Osteoporosis (%)	25.4	4.9	0.007	26.3	8.8	0.04
Osteopenia (%)	27.1	22.0	ns	26.3	8.6	ns
Osteoporotic fractures (%)	6.5	1.8	ns	6.1	3.9	ns
Osteoporosis treatment						
Calcium supplementation (%)	74.0	75.4	ns	75.5	76.3	ns
Vitamin D supplementation (%)	77.9	75.0	ns	81.6	76	ns
Bisphosphonates (%)	43.4	26.3	0.04	39.6	34.2	ns

CTX, C-terminal telopeptide of type I collagen; IMT, intima-media thickness; ns, non-significant; NTX, N-terminal telopeptide of type I collagen; 25-OHD, 25(OH) vitamin D₃; PTH, parathormone.

and arterial wall thickening remained significant (ORs (95% CIs): 1.024 (1.001 to 1.048) and 1.031 (1.007 to 1.055), respectively (table 3).

In view of the association between serum PTH levels and atherosclerosis, we next wished to explore whether patients with SLE with plaque formation and/or arterial wall thickening also display reduced BMD levels. As depicted in figure 1E, an inverse correlation between femoral neck BMD values and total IMT scores was detected ($r: -0.42, p=0.008$). No significant correlation was detected between spine BMD levels and IMT scores ($r=0.20, p=0.11$, data not shown). Furthermore, patients with SLE with plaque formation exhibited increased rates of osteoporosis compared with those without (25.4% vs 4.9%, $p=0.007$, OR 95% (CI): 6.7 (1.4 to 30.9) (table 2; figure 1F)). Similarly, a higher frequency of osteoporosis was detected among patients with high IMT scores compared with those without (26.3 vs 8.8, $p=0.04$, OR 95% (CI): 3.7 (1.2 to 11.9); table 2). Following adjustment for disease duration, total steroid dose and premature menopause, osteoporosis turned to be independent risk factor for both plaque formation and arterial wall thickening in patients with SLE (ORs 95% CI: 5.3 (1.1 to 26.2) and 3.5 (1.1 to 11.4), respectively, (table 4)).

Clinical and serological associations of high PTH levels in patients with SLE

To explore the underlying aetiology of elevated PTH serum concentrations (defined as >65 pg/mL) and identify potential links to atherosclerosis in patients with SLE, we compared patients with high versus low PTH levels in terms of demographic characteristics, metabolic and disease-related features, as well as bone metabolism-related parameters. As shown in table 5, significantly lower 25-OHD concentrations were observed in the high PTH group (14.3±5.9 vs 21.1±8.7 ng/mL, $p=0.003$), with higher rates of 25-OHD deficiency (70.6% vs 47.4%). None of the patients had evidence of hypercalcaemia suggesting primary hyperparathyroidism (data not shown). Other significant associations of elevated serum PTH included age and higher LDL levels. No statistically significant differences in statin use were detected between the high versus the low PTH group (22.2% vs 14%, p -value: 0.48). Osteoporosis, osteopaenia and osteoporotic fractures displayed higher frequency in the high serum PTH group, though the differences did not reach statistical significance, possibly due to the limited patient number (table 5).

PTH and OPG/RANKL/RANK signalling pathway

In view of previously published data showing that PTH influences both OPG and RANKL gene expression,³² together with the increasingly recognised involvement of the OPG/




Figure 1 (A) Increased rates of elevated serum parathormone (PTH) levels (>65 pg/mL, hyperparathyroidism) in patients with SLE with plaque compared with those without (25% vs 3.9%, $p=0.002$). (B) No statistically significant differences in 25(OH) vitamin D₃ (25-OHD) levels in patients with SLE with or without plaque formation (20.2 ± 9.4 vs 20.2 ± 8.4 ng/mL, non-significant (ns)). (C) Increased rates of elevated serum PTH levels (>65 pg/mL, hyperparathyroidism) in patients with SLE with arterial wall thickening (intima-media thickness (IMT) scores >0.90 mm) in comparison to those with normal IMT scores (27% vs 8.7%, $p=0.012$). (D) Lack of association of 25-OHD levels with arterial wall thickening in patients with SLE (20.0 ± 9.7 vs 19.9 ± 8.7 ng/mL, ns). (E) Inverse correlation of femoral neck bone mineral density (BMD) with intima-medial thickness (IMT) score in patients with SLE by Pearson's correlation test. (F) Higher prevalence of osteoporosis in patients with SLE with plaque formation compared with those without (25.4% vs 4.9%, $p=0.007$).

RANKL/RANK signalling pathway in vascular calcification,²⁵ we aimed to explore whether OPG/RANKL/RANK pathway is activated in patients with SLE with high PTH levels. RANKL and OPG levels were measured in available sera from 28 female patients with SLE and RANKL/OPG ratio was also determined. Among them, 7 patients exhibited high serum PTH levels, while 21 had PTH concentrations within normal range. The two groups did not differ in terms of age (49.9 ± 4.2 vs 48.3 ± 5.8 years, $p=ns$), or prevalence of osteoporosis or osteopaenia (57.1% vs 52.6%). No statistically significant associations emerged between high/low PTH status and OPG and RANKL levels or RANKL/OPG ratio

Table 3 Independent associations between PTH levels with plaque formation and arterial wall thickening, after adjustment for 25-OHD serum levels, diabetes, hypertension, high cholesterol and triglyceride levels, increased BMI, advanced age and menopausal status

	PTH levels	
	OR (95% CI)	P value
Plaque	1.024 (1.001 to 1.048)	0.040
Arterial wall thickening	1.031 (1.007 to 1.055)	0.012

BMI, body mass index; 25-OHD, 25(OH) vitamin D₃; PTH, parathormone.

(164.94 ± 77.33 vs 156.60 ± 51.51 pg/mL, 2496.75 ± 1597.87 vs 2390.43 ± 1299.32 pg/mL and 14.94 ± 5.54 vs 16.82 ± 11.05 , respectively, all comparisons non-significant; online supplementary figure 1). Additionally, no statistically significant associations were detected between OPG/RANKL levels and plaque or arterial wall thickening (data not shown).

DISCUSSION

In the present study, while we confirm previous reports of an excessive atherosclerotic burden in patients with SLE, we report a novel association between increased PTH—but not 25-OHD—serum levels with both arterial wall thickening (IMT >0.9 mm) and plaque formation. Furthermore, an inverse association between femoral neck BMD values and total IMT scores was observed, together with increased rates of osteoporosis among patients with SLE with plaque formation.

Increased PTH levels have been previously linked to CVD in general population. The underlying mechanisms behind this association might be related to hypertension, metabolic syndrome, glucose intolerance and insulin resistance, previously reported in patients with hyperparathyroidism, potentially as a result of activated renin-angiotensin-aldosterone system.^{33–35} In addition, PTH has been found to influence the expression of proinflammatory endothelial factors, such as the receptor of advanced glycation end products and interleukin 6³⁶ and to promote osteoblastic differentiation of endothelial cells through induction of bone morphogenetic proteins.³⁷ Towards the same direction, arterial wall thickening,³³ endothelial dysfunction,³⁸ number of stenotic coronary arteries¹⁴ and increase in CVD mortality¹⁵ have been reported in association with high PTH levels. In the current

Table 4 Independent associations between osteoporosis with plaque formation and arterial wall thickening, after a multivariate model was applied considering potential confounders (disease duration, premature menopause and total steroid dose)

	Osteoporosis	
	OR (95% CI)	P value
Plaque	5.3 (1.1 to 26.2)	0.04
Arterial wall thickening	3.5 (1.1 to 11.4)	0.04

Table 5 Comparison of clinical and serological parameters among patients with SLE with high (defined as >65 pg/mL) and normal PTH levels (≤65 pg/mL)

	High PTH (n=18)	Normal PTH (n=99)	P value
Demographics			
Age (mean±SD), years	54.9±11.9	43.5±13.1	0.002
Female sex (%)	100	95	1.00
BMI (mean±SD), kg/m ²	25.2±3.9	25.3±5.2	0.82
Metabolic and disease-related features			
Diabetes (%)	11.1	5.9	0.35
Hypertension (%)	50.0	30.7	0.17
Cholesterol (mean±SD), mg/dL	208±35	184±37	0.40
HDL (mean±SD), mg/dL	52±11	50±17	0.49
LDL (mean±SD), mg/dL	135±33	106±34	0.004
Triglyceride (mean±SD), mg/dL	116±35	117±33	0.80
Disease duration (mean±SD), years	10.3±9.9	9.7±8.7	0.83
Photosensitivity (%)	61.1	63.4	1.00
Nephritis (%)	22.2	28.7	0.78
Abnormal renal function (%)	11.1	3.0	0.16
SLEDAI (mean±SD)	8.1±5.9	10.1±7.8	0.21
SLICC (mean±SD)	1.44±1.14	1.09±1.31	0.45
Total steroid dose (mean±SD), g	26.6±29.6	25.9±29.6	0.83
Current steroid dose (mean±SD), mg	12.1±19.4	11.0±13.2	0.65
Patients on steroids (%)	65.0	83.1	0.33
Statin use	22.2	14.0	0.47
Bone metabolism-related parameters			
Osteoporosis (%)	18.8	18.1	1.00
Osteopenia (%)	31.3	25.3	0.57
Osteoporotic fractures (%)	11.1	5.0	0.46
25-OHD (mean±SD), ng/mL	14.3±5.9	21.1±8.7	0.003
Vitamin D deficiency (<20 ng/mL) (%)	70.6	47.4	0.11
Ca (mean±SD), mmol/L	9.3±0.4	9.4±0.5	0.31
P (mean±SD), mmol/L	3.1±0.4	3.4±0.6	0.13
Ca urine (mean±SD), g/24 hours	0.13±0.09	0.15±0.17	0.90
P urine (mean±SD), g/24 hours	0.57±0.25	0.62±0.36	0.39
CTX (mean±SD), ng/mL	0.46±0.39	0.35±0.25	0.79

BMI, body mass index; CTX, C-terminal telopeptide of type I collagen; HDL, high-density lipoprotein; LDL, low-density lipoprotein; 25-OHD, 25(OH) vitamin D₃; PTH, parathormone; SLEDAI, Systemic Lupus Erythematosus Disease Activity Index; SLICC, Systemic Lupus International Collaborating Clinics.

study, none of the patients with heightened PTH levels had evidence of primary hyperparathyroidism; advanced age and reduced 25-OHD serum levels seemed to account for these cases. With the exception of a sole paediatric SLE study where no associations between serum PTH levels and IMT scores or alterations in high-density lipoprotein/low-density lipoprotein cholesterol profile were detected,³⁹ no other data have been so far available in SLE populations.

There is ample evidence of 25-OHD involvement in CVD development,^{6–8, 40} and 25-OHD deficiency has been shown to influence endothelial dysfunction in both animal models⁴¹ and patients with SLE,⁴² possibly as a result of increase in interferon activity,^{41, 43} previously shown to be involved in

SLE-related atherosclerosis.⁴⁴ In the present report, no association between atherosclerosis and 25-OHD serum levels was observed. This finding is in accord with a prospective study by Kiani *et al*⁴⁵ in 154 patients with SLE, assessing the progression of carotid/coronary atherosclerosis over a 2-year period. Similarly, in patients with SLE of Asian descent, no associations were detected between 25-OHD levels and carotid/coronary plaque or carotid IMT scores.⁴⁶ Only in a SLE cohort of predominantly African-American origin, low 25-OHD levels were found to be associated with carotid plaque formation, after adjustment for age.⁴⁷

These apparently discrepant findings could be attributed to methodological limitations in 25-OHD measurement by

immunoassay due to hydrophobic properties of the molecule.⁴⁸ Therefore, concomitant evaluation of PTH concentrations could provide more accurate information on 25-OHD status of populations under examination.

In the present study, 25-OHD deficiency was detected in 49.6% of patients with SLE, in accord with previously reported rates.²¹ It should, however, be mentioned that approximately three quarters of our patients were already receiving vitamin D supplementation in doses varying from 400 IU to 800 IU daily together with calcium, as a preventive measure against corticosteroid-induced osteoporosis. Although it has been suggested that vitamin D supplementation could have beneficial effects on endothelial function in patients with SLE,⁴⁹ in another SLE cohort higher 25-OHD levels and vitamin D/calcium supplement intake were identified as risk factors for arterial stiffness.⁵⁰ In view of a recent report where vitamin D supplementation did not lower the incidence of CV events in general population,⁵¹ its use for disorders other than bone metabolism alterations cannot be advocated; in fact, increased doses should be avoided as they could even be immunologically damaging.^{52,53}

Another key observation in the present study is the negative association between BMD levels and markers of atherosclerosis, consistent with previous findings in both SLE and Sjogren's syndrome.^{25,30,54} However, other studies on SLE did not confirm an association between the two entities.^{55,56} Deposition of hydroxyapatite crystals in atherosclerotic lesions along with osteoblast or osteoclast resembling cells in the arterial wall,³ as well as alterations in the OPG/RANKL axis and Wnt signalling^{3,30} could provide some pathophysiological clues linking CVD and osteoporosis. In the present study, examination of a small subset of our SLE cohort did not detect statistically significant associations between OPG and RANKL levels and high PTH or markers of atherosclerosis. However, larger studies along with exploration of other signalling pathways would be needed to confirm these results.

The major strength of the present study is the thorough characterisation of potential contributors to both osteoporosis and atherosclerosis in an SLE cohort, which was the primary goal of the present work. We, however, acknowledge the limited power of the present report to reliably identify comparative differences between patients with SLE and controls due to the small number of individuals included as well as the limited sample size for several comparisons does not allow for accurate inferential conclusions. Moreover, no data on vascular calcification were available which could explore the idea of calcium mobilisation from bones to vessels, as previously suggested through Wnt signalling mechanisms.³⁰ Furthermore, the rates of fractures in the present study seem to be lower compared with previous reports, potentially reflecting genetic differences, different rates of adherence to vitamin D, calcium supplements and bisphosphonates or heterogeneous SLE populations requiring different steroid doses.¹⁹ Finally, a small subset of patients included in the study had stroke and coronary disease and therefore they had possibly experienced procedures such as coronary artery bypass graft surgery or carotid endarterectomy which could affect the evaluation of carotid plaque.

CONCLUSIONS

In conclusion, in the present study, in line with previous observations in healthy and autoimmune populations, an interplay between impaired bone health and atherosclerotic disease is revealed in patients with SLE as well. Moreover, we suggest high PTH serum levels as a potential biomarker of atherosclerosis in these patients, further strengthening the idea for adequate vitamin D supplementation in these individuals.

Author affiliations

¹Department of Rheumatology, Peripheral General Hospital Athens Georgios Gennimatas, Athens, Greece

²Department of Pathophysiology, National and Kapodistrian University of Athens School of Medicine, Athens, Greece

³Department of Physiology, National and Kapodistrian University of Athens School of Medicine, Athens, Greece

⁴Peripheral General Hospital Athens Georgios Gennimatas, Athens, Greece

⁵Department of Radiology, Peripheral General Hospital Athens Georgios Gennimatas, Athens, Greece

⁶Athens Academy, Chair Medical Sciences/Immunology, Athens, Greece

⁷Joint Academic Rheumatology Program, National and Kapodistrian University of Athens School of Medicine, Athens, Greece

Contributors Conception and design: CPM, HMM. Experimental procedure: CS. Administrative support: AS. Provision of patients and controls: HMM, CPM, MG, AS. Collection and assembly of data: MG, CPM, AS. Data analysis and interpretation: CS, MG, CPM. Manuscript drafting: MG, CPM. Final approval of manuscript: all authors.

Funding This study was supported by Hellenic Rheumatology Society and Grant code 70/3/11260.

Competing interests None declared.

Patient and public involvement Patients and/or the public were not involved in the design, conduct, reporting or dissemination plans of this research.

Patient consent for publication Not required.

Ethics approval The study protocol was approved by the Ethics Committee of the General Hospital of Athens "G.Gennimatas".

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement No data are available.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

ORCID iD

Charalampos Skarlis <http://orcid.org/0000-0002-1781-2799>

REFERENCES

- den Uyl D, Nurmohamed MT, van Tuyl LHD, *et al.* (Sub)clinical cardiovascular disease is associated with increased bone loss and fracture risk; a systematic review of the association between cardiovascular disease and osteoporosis. *Arthritis Res Ther* 2011;13:R5.
- Jørgensen L, Joakimsen O, Rosvold Berntsen GK, *et al.* Low bone mineral density is related to echogenic carotid artery plaques: a population-based study. *Am J Epidemiol* 2004;160:549–56.
- Anagnostis P, Karagiannis A, Kakafika AI, *et al.* Atherosclerosis and osteoporosis: age-dependent degenerative processes or related entities? *Osteoporos Int* 2009;20:197–207.
- Kosmopoulos M, Paschou SA, Grapsa J, *et al.* The emerging role of bone markers in diagnosis and risk stratification of patients with coronary artery disease. *Angiology* 2019;70:690–700.
- Bennett BJ, Scatena M, Kirk EA, *et al.* Osteoprotegerin inactivation accelerates advanced atherosclerotic lesion progression and calcification in older ApoE^{-/-} mice. *Arterioscler Thromb Vasc Biol* 2006;26:2117–24.

- 6 Norman PE, Powell JT. Vitamin D and cardiovascular disease. *Circ Res* 2014;114:379–93.
- 7 Pilz S, Verheyen N, Grübler MR, et al. Vitamin D and cardiovascular disease prevention. *Nat Rev Cardiol* 2016;13:404–17.
- 8 Giovannucci E, Liu Y, Hollis BW, et al. 25-Hydroxyvitamin D and risk of myocardial infarction in men: a prospective study. *Arch Intern Med* 2008;168:1174–80.
- 9 Verdoia M, Schaffer A, Sartori C, et al. Vitamin D deficiency is independently associated with the extent of coronary artery disease. *Eur J Clin Invest* 2014;44:634–42.
- 10 Al Mheid I, Patel R, Murrow J, et al. Vitamin D status is associated with arterial stiffness and vascular dysfunction in healthy humans. *J Am Coll Cardiol* 2011;58:186–92.
- 11 Carrelli AL, Walker MD, Lowe H, et al. Vitamin D deficiency is associated with subclinical carotid atherosclerosis: the Northern Manhattan study. *Stroke* 2011;42:2240–5.
- 12 Blondon M, Sachs M, Hoofnagle AN, et al. 25-Hydroxyvitamin D and parathyroid hormone are not associated with carotid intima-media thickness or plaque in the multi-ethnic study of atherosclerosis. *Arterioscler Thromb Vasc Biol* 2013;33:2639–45.
- 13 Knox S, Welsh P, Bezlyak V, et al. 25-Hydroxyvitamin D is lower in deprived groups, but is not associated with carotid intima media thickness or plaques: results from pSoBid. *Atherosclerosis* 2012;223:437–41.
- 14 Shekarkhar S, Foroughi M, Moatamedi M, et al. The association of serum parathyroid hormone and severity of coronary artery diseases. *Coron Artery Dis* 2014;25:339–42.
- 15 Hagström E, Hellman P, Larsson TE, et al. Plasma parathyroid hormone and the risk of cardiovascular mortality in the community. *Circulation* 2009;119:2765–71.
- 16 Kurmann RD, Mankad R. Atherosclerotic vascular disease in the autoimmune rheumatologic woman. *Clin Cardiol* 2018;41:258–63.
- 17 Lee KS, Kronbichler A, Eisenhut M, et al. Cardiovascular involvement in systemic rheumatic diseases: an integrated view for the treating physicians. *Autoimmun Rev* 2018;17:201–14.
- 18 Choi S, Kwon S-R, Jung J-Y, et al. Prevalence and fracture risk of osteoporosis in patients with rheumatoid arthritis: a multicenter comparative study of the FRAX and who criteria. *J Clin Med* 2018;7:507.
- 19 Buitink IEM. Bone disease in connective tissue disease/systemic lupus erythematosus. *Calcif Tissue Int* 2018;102:575–91.
- 20 Cramarossa G, Urowitz MB, Su J, et al. Prevalence and associated factors of low bone mass in adults with systemic lupus erythematosus. *Lupus* 2017;26:365–72.
- 21 Mok CC, Birmingham DJ, Leung HW, et al. Vitamin D levels in Chinese patients with systemic lupus erythematosus: relationship with disease activity, vascular risk factors and atherosclerosis. *Rheumatology* 2012;51:644–52.
- 22 Hochberg MC. Updating the American College of rheumatology revised criteria for the classification of systemic lupus erythematosus. *Arthritis & Rheumatism* 1997;40:40:1725.
- 23 Vaudo G, Bocci EB, Shoenfeld Y, et al. Precocious intima-media thickening in patients with primary Sjögren's syndrome. *Arthritis Rheum* 2005;52:3890–7.
- 24 Stergiou GS, Salgami EV. World Health Organization-International Society of Hypertension (WHO-ISH), et al. New European, American and international guidelines for hypertension management: agreement and disagreement. *Expert Rev Cardiovasc Ther* 2004;2:359–68.
- 25 Ajeganova S, Gustafsson T, Jogestrand T, et al. Bone mineral density and carotid atherosclerosis in systemic lupus erythematosus: a controlled cross-sectional study. *Arthritis Res Ther* 2015;17:84.
- 26 Schousboe JT, Shepherd JA, Bilezikian JP, et al. Executive summary of the 2013 International Society for clinical densitometry position development conference on bone densitometry. *J Clin Densitom* 2013;16:455–66.
- 27 Genant HK, Wu CY, van Kuijk C, et al. Vertebral fracture assessment using a semiquantitative technique. *J Bone Miner Res* 1993;8:1137–48.
- 28 Aloia JF, Feuerman M, Yeh JK. Reference range for serum parathyroid hormone. *Endocr Pract* 2006;12:137–44.
- 29 Giannelou M, Nezos A, Fragkioudaki S, et al. Contribution of MTHFR gene variants in lupus related subclinical atherosclerosis. *Clin Immunol* 2018;193:110–7.
- 30 Gravani F, Papadaki I, Antypa E, et al. Subclinical atherosclerosis and impaired bone health in patients with primary Sjogren's syndrome: prevalence, clinical and laboratory associations. *Arthritis Res Ther* 2015;17:99.
- 31 Giannelou M, Mavragani CP. Cardiovascular disease in systemic lupus erythematosus: a comprehensive update. *J Autoimmun* 2017;82:1–12.
- 32 Huang JC, Sakata T, Pflieger LL, et al. PTH differentially regulates expression of RANKL and OPG. *J Bone Miner Res* 2004;19:235–44.
- 33 Pepe J, Cipriani C, Sonato C, et al. Cardiovascular manifestations of primary hyperparathyroidism: a narrative review. *Eur J Endocrinol* 2017;177:R297–308.
- 34 Fujii H. Association between parathyroid hormone and cardiovascular disease. *Ther Apher Dial* 2018;22:236–41.
- 35 Tomaschitz A, Pilz S, Rus-Machan J, et al. Interrelated aldosterone and parathyroid hormone mutually modify cardiovascular mortality risk. *Int J Cardiol* 2015;184:710–6.
- 36 Rashid G, Bernheim J, Green J, et al. Parathyroid hormone stimulates endothelial expression of atherosclerotic parameters through protein kinase pathways. *Am J Physiol Renal Physiol* 2007;292:F1215–8.
- 37 Cheng Z-Y, Ye T, Ling Q-Y, et al. Parathyroid hormone promotes osteoblastic differentiation of endothelial cells via the extracellular signal-regulated protein kinase 1/2 and nuclear factor-κB signaling pathways. *Exp Ther Med* 2018;15:1754–60.
- 38 Carrelli AL, Walker MD, Di Tullio MR, et al. Endothelial function in mild primary hyperparathyroidism. *Clin Endocrinol* 2013;78:204–9.
- 39 Gupta V, Tangpricha V, Yow E, et al. Analysis of relationships between 25-hydroxyvitamin D, parathyroid hormone and cathelicidin with inflammation and cardiovascular risk in subjects with paediatric systemic lupus erythematosus: an atherosclerosis prevention in paediatric lupus erythematosus (apple) study. *Lupus Sci Med* 2018;5:e000255.
- 40 Nitsa A, Toutouza M, Machairas N, et al. Vitamin D in cardiovascular disease. *In Vivo* 2018;32:977–81.
- 41 Reynolds JA, Rosenberg AZ, Smith CK, et al. Brief report: vitamin D deficiency is associated with endothelial dysfunction and increases type I interferon gene expression in a murine model of systemic lupus erythematosus. *Arthritis Rheumatol* 2016;68:2929–35.
- 42 Reynolds JA, Haque S, Berry JL, et al. 25-Hydroxyvitamin D deficiency is associated with increased aortic stiffness in patients with systemic lupus erythematosus. *Rheumatology* 2012;51:544–51.
- 43 Ritterhouse LL, Crowe SR, Niewold TB, et al. Vitamin D deficiency is associated with an increased autoimmune response in healthy individuals and in patients with systemic lupus erythematosus. *Ann Rheum Dis* 2011;70:1569–74.
- 44 Somers EC, Zhao W, Lewis EE, et al. Type I interferons are associated with subclinical markers of cardiovascular disease in a cohort of systemic lupus erythematosus patients. *PLoS One* 2012;7:e37000.
- 45 Kiani AN, Aukrust P, Ueland T, et al. Serum osteoprotegerin (OPG) in subclinical atherosclerosis in systemic lupus erythematosus. *Lupus* 2017;26:865–70.
- 46 Jung J-Y, Koh B-R, Bae C-B, et al. Carotid subclinical atherosclerosis is associated with disease activity but not vitamin D in Korean systemic lupus erythematosus. *Lupus* 2014;23:1517–22.
- 47 Ravenell RL, Kamen DL, Spence JD, et al. Premature atherosclerosis is associated with hypovitaminosis D and angiotensin-converting enzyme inhibitor non-use in lupus patients. *Am J Med Sci* 2012;344:268–73.
- 48 Fraser WD, Milan AM. Vitamin D assays: past and present debates, difficulties, and developments. *Calcif Tissue Int* 2013;92:118–27.
- 49 Reynolds JA, Haque S, Williamson K, et al. Vitamin D improves endothelial dysfunction and restores myeloid angiogenic cell function via reduced CXCL-10 expression in systemic lupus erythematosus. *Sci Rep* 2016;6:22341.
- 50 Mellor-Pita S, Tutor-Ureta P, Rosado S, et al. Calcium and vitamin D supplement intake may increase arterial stiffness in systemic lupus erythematosus patients. *Clin Rheumatol* 2019;38:1177–86.
- 51 Manson JE, Cook NR, Lee I-M, et al. Vitamin D supplements and prevention of cancer and cardiovascular disease. *N Engl J Med* 2019;380:33–44.
- 52 Autier P, Mullie P, Macacu A, et al. Effect of vitamin D supplementation on non-skeletal disorders: a systematic review of meta-analyses and randomised trials. *Lancet Diabetes Endocrinol* 2017;5:986–1004.
- 53 Lewis JR, Sim M, Daly RM. The vitamin D and calcium controversy: an update. *Curr Opin Rheumatol* 2019;31:91–7.
- 54 Ramsey-Goldman R, Manzi S. Association of osteoporosis and cardiovascular disease in women with systemic lupus erythematosus. *Arthritis Rheum* 2001;44:2338–41.
- 55 López-Robles C, Ríos-Fernández R, Callejas-Rubio JL, et al. Low bone mass and carotid atherosclerosis in lupus erythematosus patients from Granada, a City in the South of Spain. *Lupus* 2016;25:223–4.
- 56 Mendoza-Pinto C, García-Carrasco M, Jiménez-Hernández M, et al. Carotid atherosclerosis is not associated with lower bone mineral density and vertebral fractures in patients with systemic lupus erythematosus. *Lupus* 2015;24:25–31.